Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib vs Ruxolitinib in JAKi-Naive Myelofibrosis
NCT01969838Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2013
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of momelotinib dihydrochloride in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by GSK. Started Dec 2013; status: completed.
02
Drugs
momelotinib dihydrochloride
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT01969838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01969838.